HALO:NASDAQ
Halozyme Therapeutics, Inc.
$100.27
arrow_downward
-0.40%(-0.40) 1D
$99.48
arrow_downward
-0.79% (-0.79)bedtimeAfter hours
Closed: Nov 13, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HALO...
Open
$100.32
High
$101.22
Low
$99.26
Mkt. cap
11.43B
Avg. vol.
2.32M
Volume
2.28M
P/E ratio
25.52
52-wk high
$134.00
52-wk low
$61.22
EPS
$3.93
Beta
0.92
Shares outstanding
114.01M
No. of employees
423
Open
$100.32
High
$101.22
Low
$99.26
Mkt. cap
11.43B
Avg. vol.
2.32M
Volume
2.28M
P/E ratio
25.52
52-wk high
$134.00
52-wk low
$61.22
EPS
$3.93
Beta
0.92
Shares outstanding
114.01M
No. of employees
423
News stories
From web sources and news partners
Yahoo Finance
·
2 days ago
Halozyme Therapeutics (HALO) Stock Gets Fair Value Boost After Q3 Analyst Revisions
The Globe and Mail
·
2 days ago
Will HALO's Partner Royalties Drive Growth for the Rest of 2026?
Trefis
·
2 days ago
Can You Make Money Off Halozyme Stock Now?
Investing.com
·
3 days ago
Morgan Stanley downgrades Halozyme stock rating on valuation
Profile
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia
About Halozyme Therapeutics, Inc.
CEOHelen I. Torley
Employees423
Founded1998
HeadquartersSan Diego, California, United States
SectorHealth Care
IndustryBiotechnology
Websitehalozyme.com